Advertisement

Glycemic Goals

  • David J. Brillon

Abstract

Both type 1 and type 2 diabetes are accompanied by microvascular and macrovascular complications. For decades the association between chronic hyperglycemia and the development of long-term eye, kidney, and nerve disease was suspected based on animal models of diabetes1–3 and the long term observations of clinicians.4 Nonetheless, the belief that normalization of blood glucose would prevent end organ damage was not universally accepted.5

Keywords

Glycemic Control Diabetic Retinopathy Intensive Therapy Microvascular Disease Intensive Glycemic Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Engerman R, Bloodworth JM, et al. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 26: 760–9, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Engerman RL, Kern TS Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 36: 808–12, 1987.PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen AJ, McGill PD, Rosetti RG, Guberski DL, Like AA. Glomerulopathy in spontaneously diabetic rat: impact of glycemic control. Diabetes 36: 944–51, 1987.PubMedCrossRefGoogle Scholar
  4. 4.
    Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 38: 252–61, 1978.Google Scholar
  5. 5.
    Ingelfinger FJ. Debates in diabetes. N Engl J Med 296: 1228–30, 1977.PubMedCrossRefGoogle Scholar
  6. 6.
    Kroc Collaborative Study Group Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 311: 365–72, 1984.CrossRefGoogle Scholar
  7. 7.
    Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T, Sandvik L, Aagenaes O. Reduction of urinary albumin excretion after 4 years of continuos subcutaneous insulin-infusion in insulin-dependent diabetes mellitus. Acta Endocrinologica117: 19–25, 1988.Google Scholar
  8. 8.
    Lauritzen T, Frost-Larsen K, Larsen H-W, Deckert T. Steno Study Group. Effect of 1 year of near-normal blood glucose levels on retinopathy in insulin-dependent diabetes. Lancet 1: 200–4, 1983.PubMedCrossRefGoogle Scholar
  9. 9.
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–86, 1993.CrossRefGoogle Scholar
  10. 10.
    DCCT Research Group. The effects of intensive treatment of diabetes therapy on the development and progression of neuropathy. Ann Int Med 122: 561–68, 1995.CrossRefGoogle Scholar
  11. 11.
    DCCT Research Group. The effect of intensive diabetes therapy on measures of autonomic nervous system function in the DCCT. Diabetologia 41: 416–23, 1998.CrossRefGoogle Scholar
  12. 12.
    Reichard P, Nilsson BY, Rosenquist U. The effect of long term intensified treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304–9, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Implications of the Diabetes Control and Complications Trial. American Diabetes Association Position Statement. Diabetes Spectrum 6: 225–27, 1993.Google Scholar
  14. 14.
    Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. Glycosylated hemoglobin predicts the incidence and progression of diabetic retinopathy. JAMA 260: 2864–71, 1988.PubMedCrossRefGoogle Scholar
  15. 15.
    Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: X. Four year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Opthalmol 107: 244–49, 1989.CrossRefGoogle Scholar
  16. 16.
    Lasker RD. DCCT: Implications for policy and practice. N Engl J Med 329: 1035–36, 1993.PubMedCrossRefGoogle Scholar
  17. 17.
    Nathan DM. Inferences and implications. Do results from the DCCT apply in NIDDM ? Diabetes Care 18: 251–57, 1995.PubMedGoogle Scholar
  18. 18.
    Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473–86, 1995.PubMedGoogle Scholar
  19. 19.
    Balkau B, Eschwege E, Papoz L, Richard J-L, Claude J-R, Warnet J-M, Ducimetiere P. Risk factors for early death in non-insulin-dependent diabetes and men with known glucose tolerance status. Br Med J 307: 295–98, 1993.CrossRefGoogle Scholar
  20. 20.
    Hsueh WA, Law RE. Cardiovascular risk continuum: Implications of insulin resistance and diabetes. Am J Med 105(1A)4S–14S, 1998.Google Scholar
  21. 21.
    Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus Diab Res Clin Prac 28: 103–17, 1995.Google Scholar
  22. 22.
    DCCT Research Group. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the DCCT. Diabetes 44: 968–83, 1995.CrossRefGoogle Scholar
  23. 23.
    Krolewski AS, Laffel LMB, Krolewski M, Quinn M, Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria inpatients with insulin-dependent diabetes mellitus. N Engl J Med 332: 1251–55, 1995.PubMedCrossRefGoogle Scholar
  24. 24.
    Warram JH, Manson JE, Krolewski AS. Glycosylated hemoglobin and the risk of retinopathy in insulin-dependent diabetes. N Engl J Med 332: 1305–06, 1995.PubMedCrossRefGoogle Scholar
  25. 25.
    DCCT Research Group. The absence of a glycemic threshold for the development of long-term complications: The perspective of the DCCT. Diabetes 45: 1289–98, 1996.CrossRefGoogle Scholar
  26. 26.
    DCCT Research Group, Klein R, Moss S. A comparison of the study populations in the DCCT and the WESDR. Arch Int Med 155: 745–54, 1995.CrossRefGoogle Scholar
  27. 27.
    EDIC Research Group. EDIC: Design, implementation and preliminary results of a long-term follow-up of the DCCT cohort. Diabetes Care 22: 99–111, 1999.CrossRefGoogle Scholar
  28. 28.
    DCCT/EDIC Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381–89, 2000.CrossRefGoogle Scholar
  29. 29.
    Monneir VM, Bautista O, Kenny D et al. Skin collagen, glycoxidation, and cross-linking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated products versus HbAlc as markers of diabetic complications. Diabetes 45: 28998, 1996.Google Scholar
  30. 30.
    Geiss S, Herman WH, Smith PJ. Mortality in non-insulin-dependent diabetes. In Diabetes inAmerica 2“a edition. Harris M, Editor. Bethesda Md. National Institutes of Health p133–55 (NIH publ.No 95–1468 ), 1995.Google Scholar
  31. 31.
    Krolewski AS, Kosinski EJ, Warram JH et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59: 750, 1987.PubMedCrossRefGoogle Scholar
  32. 32.
    Niskanen L,Turpeinen A, Pentilla I, Uusitupa MI. Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: al5 year follow-up from the time of diagnosis. Diabetes Care 21: 1861–69, 1998.CrossRefGoogle Scholar
  33. 33.
    Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care 21: 1167–72, 1998.PubMedCrossRefGoogle Scholar
  34. 34.
    Barrett-Connor E. Does hyperglycemia really cause coronary heart disease? Diabetes Care 20: 1620–22, 1997.PubMedGoogle Scholar
  35. 35.
    DCCT Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the DCCT. Am J Cardiol 75: 894–903, 1995.CrossRefGoogle Scholar
  36. 36.
    UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–53, 1998.CrossRefGoogle Scholar
  37. 37.
    UKPDS Group. Effect of intensive blood glucose control with metformin complications on in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–65, 1998.CrossRefGoogle Scholar
  38. 38.
    Abraira C, Colwell J, Nuttall F, Clark TS, Henderson W, Comstock JP, Emanuele NV, Levin SR, Pacold I, Lee HS. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Arch Int Med 157: 181–88, 1997.CrossRefGoogle Scholar
  39. 39.
    Laasko M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Review 5: 294–315, 1997.Google Scholar
  40. 40.
    Coutinho M, Gerstein HC, Wang Y, Yusuf S The relationship between glucose and incident cardiovascular events. Diabetes Care 22: 233–40, 1999.PubMedCrossRefGoogle Scholar
  41. 41.
    Burke GL, Evans GW, Riley WA, Sharratt AR, Howard G, Barnes RW et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults: the Artherosclerosis Risk in Communities (ARIC) Study. Stroke 26: 386–91, 1995.PubMedCrossRefGoogle Scholar
  42. 42.
    Molitch M, Cleary P, Orchard T,Backlund J-Y, O’Leary DH. Change in carotid wall thickness in the DCCT/ EDIC cohort. Diabetes 50 (S2)A74, 2001.Google Scholar
  43. 43.
    DCCT Research Group. Hypoglycemia in the DCCT. Diabetes 46: 27186, 1997.Google Scholar
  44. 44.
    DCCT Research Group. Effects of intensive diabetes therapy in neuropsychological function in adults in the DCCT. Ann Int Med 124: 379–88, 1996.CrossRefGoogle Scholar
  45. 45.
    Amiel SA, Tamborlane WV, Simonson DC, Sherwin RS. Defective glucose counteregulation after strict glycemic control of insulin-independent diabetes mellitus. N Engl J Med 316: 1376–83, 1987.PubMedCrossRefGoogle Scholar
  46. 46.
    Kinsley BT, Windom B, Simonson DS. Differential regulation of counter-regulatory hormone secretion and symptoms during hypoglycemia in IDDM. Diabetes Care 18: 17–26, 1995.PubMedCrossRefGoogle Scholar
  47. 47.
    Levy CJ, Kinsley BT, Baja M, Simonson DS. Effect of glycemic control on glucose counter-regulation during hypoglycemia in NIDDM. Diabetes Care 21: 1330–38, 1998.PubMedCrossRefGoogle Scholar
  48. 48.
    Abraira C, Maki KC. Does insulin treatment increase cardiovascular risk in NIDDM? Clin Diabetes 13: 29–31, 1995.Google Scholar
  49. 49.
    American Diabetes Association Position Statement: Standards of medical care for patients with diabetes mellitus. Diabetes Care 24 (S1): S33–S43, 2001.CrossRefGoogle Scholar
  50. 50.
    El-Kebbi IM, Zeimer DC, Cook C, Miller CD, Gallina DL, Phillips LS. Comorbidity and glycemic control in patients with type 2 diabetes. Arch Int Med 161: 1295–1300, 2001.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • David J. Brillon

There are no affiliations available

Personalised recommendations